Drug-Eluting Vascular Stent System
Restenosis following nitinol stenting peaks at about 12 months in the SFA.
SUSTEND™ Drug-Delivery Technology
The Eluvia™ Stent, with Sustend™ drug-delivery technology, is designed to deliver paclitaxel when restenosis is most likely to occur.
Polymer-based technology with proven biocompatibility
- Implanted in more than 10 million vessels since 20071
- More than 20,000 patients studied in clinical trials2
Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.
More than 12 months of sustained drug release
Built on the Innova™ Stent platform, designed to provide uniform scaffolding for drug delivery while optimizing:
- Radial strength
- Fracture resistance